Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 10/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22607403 | 0.84 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL12969036 | 0.78 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL22607443 | 0.77 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL19033502 | 0.74 | HTR2B (0.46) | PNMTADRA2AADRA2BADRA2CHTR2B | |
| SCHEMBL18977627 | 0.72 | PNMT (0.43) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL22607393 | 0.72 | MAPT (0.40) | — | |
| SCHEMBL30014954 | 0.71 | ASIC3 (0.43) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL26962924 | 0.71 | ASIC3 (0.43) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL22607192 | 0.70 | WEE1 (0.33) | PNMT | |
| SCHEMBL13267322 | 0.69 | ASIC3 (0.49) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339569-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339569-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | PNMT 3792/4885ADRA2A 3936/4885ADRA2B 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.